Stock Events

Stock Events

Pacira BioSciences 

$26.35
28
-$0.25-0.94% 20:00 Today
+$0.00+0%20:01After hours

Statistics

Day High
26.65
Day Low
26.32
52W High
27.66
52W Low
18.8
Volume
447,342
Avg. Volume
561,384
Mkt Cap
1.05B
P/E Ratio
196
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29OctExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
0.55
0.67
0.79
0.91
Expected EPS
0.711571
Actual EPS
N/A

Financials

0.97%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
726.41MRevenue
7.03MNet Income

Analyst Ratings

30.25Average Price Target
The highest estimate is 38.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PCRX. It's not an investment recommendation.
Amazon
7
AMZN
Palantir Technologies
7
PLTR
Apple
6
AAPL
Microsoft
6
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceuticals division, competes in various therapeutic areas including pain management.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie competes in the chronic pain market, offering alternatives to Pacira's surgical pain solutions.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap42.46B
Teva Pharmaceutical Industries has a broad portfolio that includes pain management solutions, competing with Pacira's offerings.
AMGEN
AMGN
Mkt Cap233.78B
Amgen's focus on innovative therapies includes pain management drugs that can be seen as alternatives to Pacira's products.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. has a diverse pharmaceutical portfolio that includes pain management, competing with Pacira.
Novartis
NVS
Mkt Cap292.35B
Novartis AG has a broad portfolio in pharmaceuticals, including pain management solutions that compete with Pacira's products.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb has a range of pharmaceutical products that compete in the pain management space with Pacira.

About

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Show more...
CEO
Frank D. Lee
Employees
829
Country
United States
ISIN
US6951271005
WKN
000A1H68T

Listings

STU
DE
82P.STU
MU
DE
82P.MU
F
DE
82P.F
XNAS
US
PCRX

0 Comments

Share your thoughts

FAQ

What is Pacira BioSciences stock price today?▼
The current price of PCRX is $26.35 USD — it has decreased by -0.94% in the past 24 hours. Watch Pacira BioSciences stock price performance more closely on the chart.
What is Pacira BioSciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Pacira BioSciences stocks are traded under the ticker PCRX.
Is Pacira BioSciences stock price growing?▼
PCRX stock has risen by +2.29% compared to the previous week, the month change is a -4.6% fall, over the last year Pacira BioSciences has showed a -1.42% decrease.
What is Pacira BioSciences market cap?▼
Today Pacira BioSciences has the market capitalization of 1.05B
When is the next Pacira BioSciences earnings date?▼
Pacira BioSciences is going to release the next earnings report on October 29, 2026.
What were Pacira BioSciences earnings last quarter?▼
PCRX earnings for the last quarter are 0.73 USD per share, whereas the estimation was 0.65 USD resulting in a +12.96% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Pacira BioSciences revenue for the last year?▼
Pacira BioSciences revenue for the last year amounts to 726.41M USD.
What is Pacira BioSciences net income for the last year?▼
PCRX net income for the last year is 7.03M USD.
How many employees does Pacira BioSciences have?▼
As of September 04, 2026, the company has 829 employees.
In which sector is Pacira BioSciences located?▼
Pacira BioSciences operates in the Health & Wellness sector.
When did Pacira BioSciences complete a stock split?▼
Pacira BioSciences has not had any recent stock splits.
Where is Pacira BioSciences headquartered?▼
Pacira BioSciences is headquartered in BRISBANE, United States.